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Abstract
Coagulopathy observed in trauma patients was thought to be a resuscitation-associated phenomenon. The
replacement of lost and consumed coagulation factors was the mainstay in the resuscitation of hemorrhagic shock for
many decades. Twenty years ago, damage control surgery (DCS) was implemented to challenge the coagulopathy of
trauma. It consists of three steps: abbreviated surgery to control the hemorrhage and contamination, resuscitation
in the intensive care unit (ICU), and planned re-operation with definitive surgery. The resuscitation strategy of DCS
focused on the rapid reversal of acidosis and prevention of hypothermia through the first two steps. However,
direct treatment of coagulopathy was not emphasized in DCS.
Recently, better understanding of the pathophysiology of coagulopathy in trauma patients has led to the logical
opinion that we should directly address this coagulopathy during major trauma resuscitation. Damage control
resuscitation (DCR), the strategic approach to the trauma patient who presents in extremis, consists of balanced
resuscitation, hemostatic resuscitation, and prevention of acidosis, hypothermia, and hypocalcemia. In balanced
resuscitation, fluid administration is restricted and hypotension is allowed until definitive hemostatic measures
begin. The administration of blood products consisting of fresh frozen plasma, packed red blood cells, and
platelets, the ratio of which resembles whole blood, is recommended early in the resuscitation.
DCR strategy is now the most beneficial measure available to address trauma-induced coagulopathy, and it can
change the treatment strategy of trauma patients. DCS is now incorporated as a component of DCR. DCR as a
structured intervention begins immediately after rapid initial assessment in the emergency room and progresses
through the operating theater into the ICU in combination with DCS. By starting from ground zero with the
performance of DCS, DCR allows the trauma surgeon to correct the coagulopathy of trauma. The effect of the
reversal of coagulopathy in massively hemorrhagic patients may change the operative strategy with DCS.
Keywords: Damage control resuscitation, Acute traumatic coagulopathy, Massive transfusion protocol, Damage
control surgery, Balanced resuscitation
Background
Massive bleeding following injury remains the main cause
of death in trauma patients. Uncontrolled hemorrhage is
reported to be responsible for 40% of trauma deaths [1].
The central measure for controlling such bleeding incor-
porated physical hemostatic approaches, such as surgery
or interventional radiology. Coagulopathy had been
thought to be a resuscitation-induced phenomenon, and
replacement of the lost and consumed coagulation factors
was the mainstay in the resuscitation of hemorrhagic
shock. Recently, better understanding of the pathophysi-
ology of coagulopathy in trauma patients has led to the
logical opinion that we should directly address coagu-
lopathy during major trauma resuscitation. Damage
control resuscitation (DCR) is a strategic approach to
the trauma patient who presents in extremis. In this
review article, the pathophysiology of the coagulopathy
in trauma patients, the theoretical and practical aspects
of DCR, and the revolution of damage control surgery
(DCS) incorporated with DCR are discussed.
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Traditionally, the coagulopathy observed in trauma
patients was thought to be “resuscitation-associated
coagulopathy,” which is caused by the consumption of
coagulation factors, dilution of coagulation factors after
massive infusion, hypothermia, and acidosis. An increas-
ing incidence of coagulopathy was observed with in-
creasing amounts of intravenous fluids administered [2].
The administration of large amounts of fluids and blood
products, exposure of the body, and surgical interven-
tion performed for resuscitation cause the hypothermia.
The alcohol and drugs, which are one of the causes of
trauma incident, increase heat loss from the trauma pa-
tient. Hypothermia is observed in about 60% of trauma
patients who require emergency operative interventions
[3]. It is associated with platelet dysfunction and reduced
enzyme activities [4] and an increased risk of bleeding
and mortality of trauma patients [5]. Inadequate tissue
perfusion due to hemorrhagic shock results in anaerobic
metabolism and the subsequent production of lactic
acid, which causes metabolic acidosis. The high chloride
content in crystalloid solutions, such as 0.9% normal sa-
line, exacerbates the metabolic acidosis [6, 7]. The activity
of most of the coagulation factors is dependent on the
blood pH. For example, the activity of factors VIIa and
Xa/Va decreases by over 90% [8] and 70% [9], respectively,
when the blood pH decreases from 7.4 to 7.0.
A vicious cycle
In 1982, Kashuk and his colleagues emphasized the im-
portance of coagulopathy in their clinical review of 161
patients with major abdominal vascular injury [10]. They
reported that most of the deaths were a result of
hemorrhage, and overt coagulopathy was identified in
51% of patients after vascular control was achieved.
The term “lethal triad” was used to describe the
physiologic derangement observed in these patients and
refers to the triad of the deteriorating status of acute co-
agulopathy, hypothermia, and acidosis of exsanguinating
trauma patients. The lethal triad forms a downward
spiral, and further hemorrhage deteriorates the triad.
Unless this cycle can be broken, the patient’s death is
unavoidable. From this aspect, this downward spiral is
known as the “vicious cycle of trauma” or the “bloody
vicious cycle,” which demands as much attention from
the physician as the classically emphasized initial resus-
citation and operative intervention.
Acute traumatic coagulopathy
Recently, injury itself is reported to cause early coagu-
lopathy [11, 12], which is known as “trauma-induced co-
agulopathy” [13] or “acute traumatic coagulopathy
(ATC)” [14]. ATC is an obvious early coagulopathy and
occurs prior to significant dilution [14, 15], within 30 min
of injury [12], and affects a quarter of the patients with
severe trauma [14]. The patients with this coagulopathy
have higher mortality than those with normal clotting
function [14].
Although the pathophysiology of ATC is not fully
understood, it is thought to occur following injury and
concomitant hypoperfusion [16]. ATC is affected primar-
ily through activated protein C, which causes both anti-
coagulant effects and fibrinolytic effects by inhibiting
plasminogen activator inhibitor-1. Instead of the import-
ance of tissue factor, another group has argued that the
coagulopathy in trauma is one of disseminated intravas-
cular coagulation with a fibrinolytic phenotype, which is
characterized by activation of the coagulation pathways,
insufficient anticoagulation mechanisms, and increased
fibrinolysis [17, 18].
These recent understandings of ATC have guided the
principle and practice of DCR, which directly addresses
the hemostatic dysfunction of the severely injured patient.
Damage control resuscitation
Management of coagulopathy in trauma patients
In the severely injured patient, unless the lethal triad of
hypothermia, acidosis, and coagulopathy is prevented,
death is unavoidable [19]. DCS is a resuscitation strategy
that was devised to avoid these physiological disorders.
It consists of three steps: abbreviated surgery to control
the hemorrhage and contamination, resuscitation in the
intensive care unit (ICU), and planned re-operation with
definitive surgery [20]. The resuscitation strategy of DCS
focused on the rapid reversal of acidosis and the preven-
tion of hypothermia through the first two steps. However,
direct treatment of coagulopathy was not emphasized in
DCS. The coagulopathy observed in hemorrhagic patients
was thought to be a result of resuscitation, acidosis, and
hypothermia. Thus, the aim of DCS was to avoid the acid-
osis and hypothermia resulting from aggressive definitive
surgery. Little attention was paid to the early derangement
of coagulation function caused by the trauma itself. In
contrast, DCR directly addresses the trauma-induced co-
agulopathy immediately upon patient admission [21] or in
the pre-hospital setting [22]. DCR consists of balanced re-
suscitation, hemostatic resuscitation, and prevention of
acidosis, hypothermia, and hypocalcemia.
Balanced resuscitation
The patient’s response to the rapid infusion of isotonic
fluid or blood is the indicator of the need for surgical or
interventional hemostatic procedures. Aggressive fluid
resuscitation was the initial fluid therapy recommended
for many decades. However, this approach may contribute
to increased blood loss and higher mortality [23]. The
warning concerning the massive administration of fluid
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was already reported about 100 years ago by Captain
Cannon [24]. He commented that, “There is no doubt
that in some cases such injections have had definitely
beneficial effects, however, the injection of a fluid, that
will increase blood pressure, has dangers in itself. If the
pressure is raised before the surgeon is ready to check
any bleeding, blood needed may be lost.”
Increasing evidence has shown that aggressive
crystalloid-based resuscitation strategies are associated
with cardiac and pulmonary complications [25], gastro-
intestinal dysfunction, coagulation disturbances, and
disorders of immunological and inflammatory media-
tors [26]. The administration of large volumes of fluids
results in imbalances of intracellular and extracellular
osmolarity that affect cell volume. Disturbances in cell
volume then disrupt numerous regulatory mechanisms
responsible for controlling the inflammatory cascade.
For these reasons, an alternative approach to the treat-
ment of hemorrhagic patients was recently proposed
and practiced. The approach was introduced as permis-
sive hypotension, delayed resuscitation, or controlled
resuscitation. The aim of these resuscitation strategies
is not hypotension but rather to balance the risk of
decreased tissue perfusion with the benefits from the
prevention of coagulopathy.
In 1994, Bickell and colleagues investigated the benefit
of delayed fluid resuscitation in a randomized controlled
trial. Five hundred eighty-nine adult patients with pene-
trating injuries and a pre-hospital systolic blood pressure
of less than 90 mmHg were enrolled in the trial [27].
The application of delayed fluid resuscitation increased
the survival rate of of the patients from 62 to 70%.
After this report, several randomized or retrospective
studies concerning balanced resuscitation were reported;
however, the benefit to mortality varied among the studies
[28–31]. Turner et al. randomized more than 1000 pa-
tients to immediate or delayed resuscitation in the pre-
hospital setting but showed no beneficial effects on
mortality [28]. Both Dutton et al. and Morrison et al.
investigated the effects of hypotensive resuscitation in
about 100 patients, but the results varied between these
two reports [29, 30]. Duke et al. retrospectively com-
pared cohorts with standard and restricted fluid resus-
citation and reported that restricted fluid resuscitation
showed a survival benefit [31].
When evaluating the effects of balanced resuscitation,
these results should be interpreted cautiously. The
patients enrolled in the Bickell et al. and Duke et al.
reports were victims of penetrating injury only. In the
reports of Morrison et al. and Dutton et al., the rates of
patients with penetrating injury were 93 and 51%, re-
spectively. The time from hospital arrival to the emer-
gency operation was very short, and furthermore, the
patients were in their 20s or 30s. There are other
concerns, such as the low protocol compliance in the
Turner et al. report and the difficulty of controlling the
blood pressure at the aimed-for level in the Dutton et al.
and Morrison et al. reports.
The ninth edition of the Advanced Trauma Life Sup-
port emphasizes the concept of balanced resuscitation,
and the term “aggressive resuscitation” has been elimi-
nated. The standard use of 2 L of crystalloid resuscita-
tion as the starting point for all resuscitation has been
modified to the initiation of 1 L of crystalloid infusion.
Early use of blood and blood products for patients in
shock is emphasized [32].
The most recent randomized controlled trial to evalu-
ate the efficacy of balanced resuscitation was reported in
2015 [33]. This multicenter study was performed in 19
emergency medical services systems in the USA and
Canada. The controlled resuscitation resulted in a reduc-
tion of early crystalloid resuscitation volume and an
increase in the early transfusion of blood products.
Although mortality at 24 h was not different among all
patients, it improved in the subgroup with blunt trauma.
The controlled resuscitation strategy can be successfully
and safely implemented in a civilian environment begin-
ning with the out-of-hospital setting and extending into
early hospital care.
Hemostatic resuscitation
In 2007, Borgman and Holcomb et al. reported a survival
benefit for the high ratio of plasma to red blood cell
(RBC) in patients who received massive transfusions at a
combat support hospital [34]. A high plasma to RBC ratio
(1:1.4) was independently associated with improved
survival, primarily by decreasing death from hemorrhage.
Following this article, several studies investigating the sur-
vival benefit of a high ratio of fresh frozen plasma (FFP) to
RBC were reported [35–40]. Although the ratio of FFP to
RBC differed between the studies, a significant decrease in
the mortality of the massively transfused patients in the
high-ratio population as compared to the low-ratio popu-
lation was achieved in both the civilian setting and the
combat situation.
However, it remains controversial which ratio, 1:1 or
1:2, is beneficial and when the ratio should be achieved.
Snyder et al. worried about the survival bias in the bene-
ficial results observed in the retrospective studies [41].
Holcomb and colleagues investigated the relationship
between in-hospital mortality and the early transfusion
of plasma or platelets, and time variance in the delivery
of plasma to RBC or platelet to RBC ratios in a multi-
center prospective observational study [42]. The number
of patients receiving the higher ratio rose as time passed.
In the first 6 h, patients receiving a ratio of less than 1:2
were three to four times more likely to die than patients
receiving a ratio of 1:1 or higher. They concluded that
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the earlier and higher ratio of plasma to RBCs decreased
in-hospital mortality, and this beneficial effect was en-
hanced when the high ratio was achieved in the first
6 h after admission. In the Japan-Observational study
for Coagulation and Thrombolysis in Early Trauma (J-
OCTET), 189 severe trauma adult patients were regis-
tered [43]. Although the area under the curve was not
high, the receiver operating characteristic curve analysis
showed that the FFP/RBC ratio of 1.0 resulted in max-
imum sensitivity and specificity for survival. They con-
cluded that a transfusion with an FFP/RBC ratio over
1.0 within the first 6 h reduces the risk of death by
about 60% in patients with blunt hemorrhagic trauma.
The most recent randomized trial to evaluate the
suitable ratio of plasma to RBCs for patients with se-
vere trauma and major bleeding was performed in the
pragmatic, randomized optimal platelet and plasma ra-
tios (PROPPR) study [44], in which 680 patients were
randomized to receive either a 1:1:1 or 1:1:2 ratio of
plasma, platelets, and RBCs. Although the mortality
was not significantly different between the two groups,
more patients in the 1:1:1 group achieved hemostasis.
Exsanguination, which was the predominant cause of
death within the first 24 h, was significantly decreased
in the high-ratio group.
Rewarming
In DCR, hypothermia should be managed in conjunction
with the efforts to correct the trauma-induced coagulop-
athy. It is essential to rewarm the torso using passive
warming measures, such as insulting foil, blankets, and
the removal of wet clothes. The initial fluid resuscitation
should be carried out with warmed infusions at a fluid
temperature of 40–42 °C [5, 45]. Heated air inhalation,
gastric or body cavity lavage with warmed fluids, and
heat radiation are widely performed as well as the stan-
dardized use of warming measures with rapid infusers.
The temperature in the emergency room and the operat-
ing room should be raised, at best to a thermally neutral
range (28–29 °C) [46]. If the hypothermia persists or
quickly relapses despite these maximal rewarming
efforts, ongoing hemorrhage and unresolved tissue hy-
poperfusion and hypoxia should be suspected.
Reversing acidosis
Buffering of metabolic acidosis using drugs not only
aggravates the intracellular acidosis but also does not
reverse the coagulopathy [47]. Reversal of metabolic
acidosis in the trauma patient is better obtained through
fluid and blood resuscitation and vasopressor support
with surgical control of hemorrhage. Shock should be
reversed and end-organ perfusion is restored [48]. Be-
cause vital signs such as blood pressure and heart rate
are not adequate to evaluate peripheral tissue perfusion,
several endpoints of resuscitation are addressed. Base
deficit and lactate levels are the reliable indices with
which to evaluate the adequacy of the resuscitation and
end-organ perfusion. Not only the initial lactate value
upon admission but also lactate clearance from plasma
within the first few hours of resuscitation correlate with
the mortality of trauma patients [49, 50].
Tranexamic acid
Because hyperfibrinolysis was recognized to contribute
to the acute coagulopathy in trauma, administration of
antifibrinolytic agents had theoretical benefit. The clin-
ical randomization of an antifibrinolytic in significant
hemorrhage 2 (CRASH-2) study, a large multi-center
randomized controlled trial, investigated the effect of
tranexamic acid on mortality and blood product require-
ments in trauma patients with hemorrhagic shock [51].
The study was undertaken in 274 hospitals in 40 coun-
tries. More than 20,000 adult trauma patients were ran-
domized to receive either tranexamic acid or placebo
within 8 h of injury. All-cause mortality and the risk of
death due to bleeding were significantly decreased with
the administration of tranexamic acid. Maximal benefi-
cial effects were achieved if it was given within the first
3 h of injury. However, a recent study indicated that the
majority of severely injured patients have fibrinolysis
shutdown, and therefore, tranexamic acid may have no
effect [52, 53]. The greatest benefit of tranexamic acid
may be in patients in whom increased clot lysis is shown
to be present using thromboelastography.
Fibrinogen concentrates
Fibrinogen plays a central role in the coagulation
process. It bridges activated platelets and works as the
key substrate of thrombin to generate a stable fibrin
mesh. In patients with blood loss, fibrinogen has been
reported to decrease more rapidly under critically low
concentrations than the other coagulation factors [54].
Thus, the supplementation of fibrinogen is a measure
that makes sense when treating the coagulopathy of
trauma patients. The effect of the administration of
fibrinogen concentrates on outcome was investigated by
matched-pairs analysis using the German Trauma Regis-
try [55]. Although 30-day mortality was comparable, 6-h
mortality was significantly lower in the patients receiving
fibrinogen. The fibrinogen concentrates might have de-
layed the cause of death from early hemorrhagic collapse
to late multiple organ failure.
Prothrombin complex concentrate
Recently, prothrombin complex concentrate, derived
from human plasma and contains variable amounts of
factors II, VII, IX, and X, is used to correct coagulopathy
[56, 57]. Goal-directed coagulation management using
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thromboelastometry was used to evaluate requirements
of clotting factors [56, 57]. The administration of fi-
brinogen concentrate alone or in combination with pro-
thrombin complex concentrate resulted in a significant
improvement of fibrin polymerization and shorter clot-
ting time [56]. Schochl et al. used fibrinogen concentrate
and prothrombin concentrate complex as first-line ther-
apies for coagulopathy based on thromboelastography in
a study of 131 severely injured patients [57]. Transfusion
of fresh frozen plasma and cryoprecipitate was avoided
in the vast majority of these patients and outcomes were
better than predicted.
Cryoprecipitate
In the countries, where administration of fibrinogen
concentrates is not approved in trauma patients, cryopre-
cipitate is the alternative treatment option as a source of
fibrinogen. However, there are no reports suggesting posi-
tive effects of cryoprecipitate administration on the sur-
vival of exsanguinating trauma patients [58–60]. Although
cryoprecipitate contains high concentrations of fibrinogen,
it is hampered by several relevant disadvantages in terms
of its availability, allogenicity, and the need for blood type
matching and time-consuming thawing. Because the
timing and indications for the administration of cryo-
precipitate were unclear in the previously reported
studies, a prospective randomized trial will be required
to evaluate its benefit [59].
Calcium
Calcium acts as an important cofactor in the coagulation
cascade. Low levels of ionized calcium at admission are
associated with increased mortality and an increased re-
quirement for massive transfusion [61, 62]. Citrate, which
is used as an anticoagulant in blood product components,
chelates calcium and exacerbates the hypocalcemia, par-
ticularly when used in the FFP. The faster the transfusion
is given, the faster the reduction of the calcium concentra-
tion occurs [63]. An ionized calcium concentration of
less than 0.6–0.7 mmol/L could lead to coagulation
defects. In addition, contractility of the heart and
systemic vascular resistance are diminished under de-
creased ionized calcium levels. Because of its combined
beneficial cardiovascular and coagulation effects, the
calcium concentration should be monitored periodically
with every ten units of transfusion, and it is recom-
mended that a concentration of at least 0.9 mmol/L be
maintained [64, 65].
Massive transfusion protocol
Massive transfusion is typically defined as the transfu-
sion of ten or more units of packed red blood cells
within the first 24 h of injury. It is important for the re-
suscitation staff to identify the patients who might
require massive transfusion early in the process of initial
resuscitation. Following the prediction of massive trans-
fusion, blood products should be delivered in a quick
and timely manner at a high ratio of plasma, RBCs, and
platelets. To achieve this quick response, not only the
resuscitation staff but also the blood bank staff need to
incorporate pre-implemented guidelines and flow charts
for massive transfusion protocol (MTP) into their work
flow [48, 66–68]. The protocol includes patient selection
for activation of the MTP, description of the staff who
should declare the activation, and the means by which
the resuscitation team and the blood bank are informed
of the protocol’s activation. In the blood bank, cooled
packs of O negative RBCs, type AB FFP, and platelets
will be pre-packed for quick delivery. A high-ratio pack
is continually delivered each time blood is requested
until the protocol is deactivated. Type-specific blood will
be delivered as soon as the patient’s blood type is
determined.
The MTP was implemented in 85% of the trauma cen-
ters in the USA as of 2010 [69]. The MTP is bundled
with the administration of calcium, factor VIIa, and
fibrinogen. The laboratory examination of coagulation
function by thromboelastography is included as are
other standard blood laboratory tests.
The beneficial effects of the implementation of the
MTP have been reported by several authors to be re-
ductions in mortality and in the use of blood products
[67, 70, 71]. Furthermore, compliance with the protocol
affects patient outcome [66]. Because it is complex to
transfuse blood products in a timely and safe manner,
implementation of the MTP is essential for institutions
caring for severely injured trauma patients. Improved
blood bank procedures, effective and efficient rewarming
procedures, application of damage control techniques,
and aggressive correction of coagulopathy will contribute
to the survival benefit [72].
It is important to activate the MTP as quickly as pos-
sible; however, it is worth considering that massive
transfusion, especially with the administration of FFP,
has adverse effects for a subgroup of trauma patients.
Inaba and colleagues retrospectively investigated the in-
cidence opportunity following plasma transfusion in pa-
tients who did not require massive transfusion [73].
Although there was no improvement in survival with
plasma transfusion, the overall rate of complications
was significantly higher in the patients receiving plasma
products.
Several scores, such as the trauma associated severe
hemorrhage (TASH) [74], the scoring system developed
by McLaughlin [75], assessment of blood consumption
(ABC) [76], and traumatic bleeding severity score
(TBSS) [77] scores, are proposed for the prediction of
patients who require massive transfusion in the early
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phase of resuscitation. Each score includes the systolic
blood pressure and heart rate on admission or after the
initial resuscitation. The focused assessment with sonog-
raphy for trauma exam, extremity and/or pelvic injury,
sex, age, or laboratory data are assessed to calculate
these scores. Recently, the TBSS score was modified to
predict the need for massive transfusion more quickly
[78]. The systolic blood pressure on arrival but after
fluid resuscitation was used. The predictive value of the
modified TBSS is still high and is reported to be equiva-
lent to that of the TASH score.
Remote DCR
The concept and practice of the DCR is recently applied
in the pre-hospital setting and named as remote DCR
(RDCR) [79]. Not only the fixed-ratio coagulation therapy
using the high ratio of plasma and platelets to pRBC but
also the coagulation factor concentrate-based treatment is
proposed in the RDCR. It includes three major compo-
nents to a step-wise approach to achieve hemostasis: (1)
stop (hyper)fibrinolysis, tranexamic acid; (2) support clot
formation, fibrinogen concentrate; and (3) increase throm-
bin generation, prothrombin complex concentrate [22].
Although RDCR warrants further investigation concern-
ing its effect on the mortality or the blood products re-
quirement, and the assessment of the patient’s coagulation
function in the instrument limited environment, the tran-
examic acid has been implemented in the RDCR in the
US, French, British, and Israeli militaries as well as the
British, Norwegian, and Israeli civilian ambulance services.
A prospective cohort study in the civilian trauma center
demonstrated reduction in mortality and multiple organ
failure for patients treated with tranexamic acid in the
subgroup of patients with shock [80]. In the report of
Wafaisade et al., the propensity score matched analysis
using the German trauma database demonstrated the pro-
longed time to death and reduction in early mortality in
the tranexamic acid-administered trauma patients [81].
The updated European guideline suggests the administra-
tion of the first dose of tranexamic acid en route to the
hospital as a grade 2C recommendation [82].
DCR and DCS
Adverse effects of DCS
After the recognition of the vicious cycle in trauma
patients, a paradigm shift in the surgical treatment of
severely hemorrhagic patients occurred. DCS was
developed to challenge the lethal triad of trauma. It was
originally reported by Stone and colleagues in 1983 [83]
and named by Rotondo and Schwab in 1993 [20]. Since
these reports, DCS has become the standard of care for
the most severely injured patients. It has been widely
applied not only for abdominal trauma but also for
thoracic [84], vascular [85], pelvic [86], and extremity
injuries [87, 88]. DCS has led to better outcomes in
severely hemorrhagic patients [89]. Ten years of experi-
ence have shown that patients who receive DCS for
penetrating abdominal trauma have higher survival rates
and a decreased incidence of hypothermia in the operat-
ing room [90]. In the early decades after DCS was intro-
duced, it was performed in cooperation with aggressive
volume resuscitation.
Although DCS was popularized and resulted in re-
duced mortality, the abbreviated surgical techniques and
open abdomen management led to significant increases
in sub-acute complications, such as open abdomen,
acute respiratory distress syndrome, intra-abdominal
infections, and multiple organ failure [91]. In particular,
open abdomen management resulted in an increase in
severe morbidities, such as anastomotic breakdown,
ventral hernias, and enteroatmospheric fistula [92, 93].
Aggressive resuscitation increased the incidence of
these complications [26].
Studies have recently warned against the overuse of
DCS [94, 95]. Clinical outcomes may be improved with
more selective use of DCS accompanied by DCR [96].
Changes of surgical strategy in DCR
The severely hemorrhagic patient has a limited amount
of physiologic reserve before irreversible derangement,
organ damage, and collapse occur. DCR restores this
reserve, allowing more definitive treatment that results
in decreased postoperative complications and improved
outcomes [40, 68].
DCS is now incorporated as a component of DCR and
should not be practiced in isolation [64]. DCR as a
structured intervention should begin immediately after
rapid initial assessment in the emergency room and
progresses through the operating theater into the ICU
in combination with DCS [48].
By starting from ground zero with the performance
of DCS, DCR allows the trauma surgeon to correct the
lethal triad, particularly the coagulopathy of trauma.
Definitive therapy can be completed at the first oper-
ation in patients who are warm, well perfused, and
without coagulopathy [97, 98].
Higa and colleagues reported that DCR increased the
administration of blood products with less infusion of
crystalloid solution and was associated with a survival
advantage and shorter length of stay in the trauma ICU
for patients with severe hemorrhage [96]. Although the
number of laparotomy patients increased, the number of
patients requiring damage control laparotomy decreased
from 36 to 9%, and the mortality for patients requiring
open laparotomy improved from 22 to 13%. The applica-
tion of DCR to damage control laparotomy techniques
results in an improvement in the ability to achieve pri-
mary fascia closure and decreases the requirement for
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staged laparotomy [99]. In addition, DCR may decrease
the surgical hemostatic requirement in severely injured
patients. A retrospective study showed an increase in the
success rate of nonoperative management from 54 to
74% for grades IV and V severe blunt liver injury after
the implementation of DCR [100]. DCR may herald the
beginning of the end for DCS [98].
Conclusions
DCR strategy is the measure that directly addresses
trauma-induced coagulopathy. Although several concerns,
such as the plasma to RBCs ratio, the method of achieving
balanced resuscitation, and the administration of other
coagulation factors, are not completely resolved, it is now
the most beneficial measure for treating trauma-induced
coagulopathy, and it can change the treatment strategy of
trauma patients. The effect of the reversal of coagulopathy
in the massively hemorrhagic patient may shift the opera-
tive strategy from one of DCS to definitive surgery.
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